





## COPA: Constrained PARAFAC2 for Sparse & Large Datasets


Ardavan (Ari) Afshar<sup>1</sup>, Ioakeim Perros<sup>1</sup>, Evangelos E. Papalexakis<sup>2</sup>, Elizabeth Searles<sup>3</sup>, Joyce Ho<sup>4</sup>, Jimeng Sun<sup>1</sup>

<sup>1</sup>Georgia Tech, <sup>2</sup>UC Riverside

<sup>3</sup>Children's Healthcare of Atlanta, <sup>4</sup>Emory University




## Computational Phenotyping from Electronic Health Records (EHRs)




#### (Phenotyping with Tensor Factorization)

Regular Tensor Factorization Approaches (CP Decomposition)




#### Challenges: Temporal Mismatch in Phenotyping

Variable # hospital visits.




#### Background: PARAFAC2

Input data: K subjects (patients), J medical feature and  $I_k$  hospital visits per patient.



#### Model Interpretation for phenotyping via EHRs



evolution of phenotype r.


Each **column** of *V* represents a **phenotype**.

#### Contributions of COPA


	Marble	Rubik	PARAFAC2	SPARTan	Helwig	СОРА
Smoothness					✓	<b>✓</b>
Sparsity	✓	<b>√</b>				$\checkmark$
Scalability				<b>✓</b>		<b>✓</b>
Handle irregular tensors			<b>√</b>	<b>√</b>	<b>√</b>	<b>√</b>

- Ho, Joyce C., Joydeep Ghosh, and Jimeng Sun. "Marble: high-throughput phenotyping from electronic health records via sparse nonnegative tensor factorization." Proceedings of the 20th ACM SIGKDD international conference on Knowledge discovery and data mining. ACM, 2014.
- Wang, Yichen, et al. "Rubik: Knowledge guided tensor factorization and completion for health data analytics." Proceedings of the 21th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. ACM, 2015.
- Kiers, Henk AL, Jos MF Ten Berge, and Rasmus Bro. "PARAFAC2—Part I. A direct fitting algorithm for the PARAFAC2 model." *Journal of Chemometrics: A Journal of the Chemometrics Society* 13.3-4 (1999): 275-294.
- Kiers, Henk AL, Jos MF Ten Berge, and Rasmus Bro. "PARAFAC2—Part I. A direct fitting algorithm for the PARAFAC2 model." Journal of Chemometrics: A Journal of the Chemometrics Society 13.3-4 (1999): 275-294.
- Helwig, Nathaniel E. "Estimating latent trends in multivariate longitudinal data via Parafac2 with functional and structural constraints." Biometrical Journal 59.4 (2017): 783-803.


### Smoothness on $U_k$




#### Creating Basis Functions



Ignoring the gap between two hospital visits



#### COPA Framework



$$U_k = Q_k H, Q_k^T Q_k = I$$

For all k=1,...K

$$S_k \ge 0$$
,  $H \ge 0, V \ge 0$ 

For all k=1,...K


Non-negativity constraint

## Solution for factor matrix $\{Q_k\}$


$$\begin{aligned} & \text{Minimize} \quad \frac{1}{2} \left| |X_k - Q_k H S_k V^T| \right|_F^2 \\ & & \text{Trace Properties} \end{aligned}$$
 
$$\begin{aligned} & \text{Minimize} \quad \frac{1}{2} \left| |X_k V S_k H^T - Q_k| \right|_F^2 \\ & & \text{Apply SVD} \end{aligned}$$
 
$$[B_k, \Sigma_k, C_k] = SVD(X_k V S_k H^T) \\ & Q_k = B_k C_k^T \end{aligned}$$

## Solutions for factor matrices H, $\{S_k\}$ , V

$$||X_k - Q_k H S_k V^T||_F^2$$



$$\left\| Q_K^T X_k - H S_k V^T \right\|_F^2$$



## Sparsity on V

#### Real Datasets Description

- Children Healthcare of Atlanta (CHOA):
  - ✓ Medical features contain diagnosis and medications.
  - ✓ Hospital visits are based on days of visits.
- Centers for Medicare and Medicaid (CMS):
  - ✓ CMS is a set of realistic data set publicly available, however, protecting the privacy of patients.
  - ✓ Medical features just contains diagnosis.

Dataset	# Patients	# Medical Features	# Hospital visits	#non-zero elements
CHOA	247,885	1388	857	11 Million
CMS	843,162	284	1500	84 Million

#### **Evaluation Metrics**

FIT 
$$= 1 - \frac{\sum_{k=1}^{K} ||X_k - U_k S_k V^T||_F^2}{\sum_{k=1}^{K} ||X_k||_F^2}$$

Higher better

$$=\frac{nz(V)}{size(V)}$$

Higher better


Running-Time

(In Seconds)

Lower better

#### Quantitative assessment of Constraints

This plot shows the impact of each constraint on the FIT values across both datasets for two different target ranks ( $R=\{15,40\}$ )



Higher better

R={15,40}

CHOA, CMS

<sup>\*</sup> The missing purple bar in the forth column is out of memory failure for Helwig method.

#### Quantitative assessment of Constraints


#### **Sparsity Metric**

	СН	OA	CMS		
Algorithm	R=15	R=40	R=15	R=40	
COPA	0.9886±0.0035	0.9897±0.0027	$0.995 \pm 0.0001$	0.9963±0.0002	
SPARTan	0.7127±0.0161	0.8127±0.0029	0.1028±0.0032	0.2164±0.0236	

Higher better


5 different random initialization

### Scalability



The Total Running Time comparison (average and standard deviation) in seconds for different versions of COPA and SPARTan for 5 different random initializations.


#### FIT-TIME (Convergence)




The best Convergence of COPA and SPARTan out of 5 different random initializations with non-negativity constraint on H,  $\{S_k\}$ , V on CHOA, CMS data sets for different target ranks (two cases considered:  $R=\{15,40\}$ )

### Scalability

Time in seconds for one iteration (as an average of 5 ) for different values of R.





#### Case Study: CHOA Phenotype Discovery

# Children's Healthcare of Atlanta

Focus on Medically Complex Patients (MCPs)

A total of **4602** patients are selected with **810** distinct medical features. We extracted 4 number of phenotypes.

#### Our goal is:

- Extracting the phenotypes
- Find the temporal evolution of phenotypes for each patient.

#### Phenotypes Discovered by COPA

#### Leukemias

Leukemias

Immunity disorders

Deficiency and other anemia

HEPARIN AND RELATED PREPARATIONS

Maintenance chemotherapy; radiotherapy

ANTIEMETIC/ANTIVERTIGO AGENTS

SODIUM/SALINE PREPARATIONS

TOPICAL LOCAL ANESTHETICS

GENERAL ANESTHETICS INJECTABLE

**ANTINEOPLASTIC - ANTIMETABOLITES** 

**ANTIHISTAMINES - 1ST GENERATION** 

ANALGESIC/ANTIPYRETICS NON-SALICYLATE

ANALGESICS NARCOTIC ANESTHETIC ADJUNCT AGENTS

ABSORBABLE SULFONAMIDE ANTIBACTERIAL AGENTS

**GLUCOCORTICOIDS** 

#### **Neurological Disorders**

Other nervous system disorders

Epilepsy; convulsions

Paralysis

Other connective tissue disease

Developmental disorders

Rehabilitation care; and adjustment of devices

**ANTICONVULSANTS** 

#### Congenital anomalies

Other perinatal conditions

Cardiac and circulatory congenital anomalies

Short gestation; low birth weight

Other congenital anomalies

Fluid and electrolyte disorders

LOOP DIURETICS


IV FAT EMULSIONS

#### Sickle Cell Anemia

Sickle cell anemia Other gastrointestinal disorders Other nutritional; endocrine; and metabolic disorders Other lower respiratory disease Asthma Diagnosis Allergic reactions Esophageal disorders Respiratory failure; insufficiency; arrest (adult) Other upper respiratory disease **BETA-ADRENERGIC AGENTS ANALGESICS NARCOTICS** NSAIDS, CYCLOOXYGENASE INHIBITOR - TYPE ANALGESIC/ANTIPYRETICS NON-SALICYLATE POTASSIUM REPLACEMENT SODIUM/SALINE PREPARATIONS **GENERAL INHALATION AGENTS** Medication LAXATIVES AND CATHARTICS IV SOLUTIONS: DEXTROSE-SALINE ANTIEMETIC/ANTIVERTIGO AGENTS SEDATIVE-HYPNOTICS NON-BARBITURATE GLUCOCORTICOIDS, ORALLY INHALED FOLIC ACID PREPARATIONS ANALGESICS NARCOTIC ANESTHETIC ADJUNCT AGENTS

Title annotation is provided by a medical expert.

#### Temporal Phenotyping







aafshar8@gatech.edu



http://www.prism.gatech.edu/~aafshar8/




https://github.com/aafshar/COPA













Ari Afshar

Kimis Perros

Vagelis Papalexakis

Bess Searles

Joyce Ho

Jimeng Sun









